Journals / Journal of the Turkish-German Gynecological Association / 2011 / Cilt: 12 - Sayı: 4

Adneksiyel kitlelerde malignite prediksiyonunda tümör belirteci olarak serumda crp, vegf, leptin, ck-mb, ca-15-3, ıl-6 bakılması

Determination of serum crp, vegf, leptin, ck-mb, ca-15-3 and il-6 levels for malignancy prediction in adnexal masses

Pages
214–219
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: CA 15-3, IL-6, Leptin, VEGF and CRP were effective in the prediction of benign and malignant masses; however they may be more suitable in selected cases as they have a limited use because of their inadequate potential regarding sensitivity and specificity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Investigation of serum markers which could be used in the malignancy prediction of adnexal masses.
📊
Key Findings & Data:Material and Methods: Vascular endothelial growth factor (VEGF), interleukin 6 (IL-6), leptin, C-reactive protein (CRP), creatine-kinase-MB (CK-MB) and cancer antigen 15-3 (CA 15-3) levels were determined prospectively in serum samples that were obtained from patients who underwent surgery for an adnexal mass and who were referred to Istanbul University, Faculty of Medicine, Department of Obstetrics and Gynecology, between 2009 and 2011, and then were compared with the serum samples of completely healthy outpatient patients as a control group.
💡
Conclusion & Impact:Conclusion: CA 15-3, IL-6, Leptin, VEGF and CRP were effective in the prediction of benign and malignant masses; however they may be more suitable in selected cases as they have a limited use because of their inadequate potential regarding sensitivity and specificity.
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Investigation of serum markers which could be used in the malignancy prediction of adnexal masses. Material and Methods: Vascular endothelial growth factor (VEGF), interleukin 6 (IL-6), leptin, C-reactive protein (CRP), creatine-kinase-MB (CK-MB) and cancer antigen 15-3 (CA 15-3) levels were determined prospectively in serum samples that were obtained from patients who underwent surgery for an adnexal mass and who were referred to Istanbul University, Faculty of Medicine, Department of Obstetrics and Gynecology, between 2009 and 2011, and then were compared with the serum samples of completely healthy outpatient patients as a control group. Based onto the ovarian cancer status, cases were divided into four groups: 13 patients were included in the early-stage malignant group, 12 patients were included in the advanced-stage malignant group, 25 in the benign group and 19 in the healthy control group. Patients with only epithelial ovarian cancer were included into the cancer group. Ethics Commitee approval was obtained for this study. The budget was supported by the Istanbul University Scientific Research Projects Unit. Results: Results related with sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and odds ratio (OR), respectively, and the following values were calculated: 48%, 95%, 92%, 59% and +OR 9.6 -OR 0.5 for CA; 15-3; 52%, 75%, 72%, 55%, +OR 2.08 -OR 0.64 for leptin; 72%, 70%, 75%, 66% 2.4-0.5 for IL-6; 24%, 80%, 60%, 45%, 1.2-0.92 for VEGF; 68%, 30%, 55%, 43%, 0.97-1.06 for CRP; and 8%, 70%, 25%, 38%, 026-1.31 for CK-MB. Conclusion: CA 15-3, IL-6, Leptin, VEGF and CRP were effective in the prediction of benign and malignant masses; however they may be more suitable in selected cases as they have a limited use because of their inadequate potential regarding sensitivity and specificity.

Özet

Amaç: Adneksiyel kitlelerde malignite ayrımında kullanılabilecek serum markerlarının araştırılması. Gereç ve Yöntemler: İstanbul Üniversitesi İstanbul Tıp Fakültesi Kadın Hastalıkları ve Doğum Anabilim Dalı’nda 2009-2011 yılları arasında prospektif olarak, adneksiyel kitle endikasyonu ile opere olan hastalardan alınan serum örneklerinde vascular endotelial growth factor (VEGF), interlökin 6 (IL-6), leptin, C-reaktif protein (CRP), kreatin kinaz-MB (CK-MB) ile kanser antijeni 15-3 (CA 15-3) düzeyleri belirlendi ve kontrol grubu olan tamamen sağlıklı poliklinik hastalarının serum örnekleriyle karşılaştırıldı. Olgular over kanseri durumuna göre 4 grupta toplandı: 13 olgu erken evre malign, 12 olgu ileri evre malign, 25 olgu benign, 19 olgu sağlıklı kontrol grubunda yer aldı. Over kanseri grubunda sadece epitelyal over kanseri olan olgular çalışmaya dahil edildi. Çalışma için etik kurul onayı alındı ve bütçe ise İstanbul Üniversitesi Bilimsel Araştırma Projeleri Birimi tarafından desteklendi. Bulgular: Belirteçlerin duyarlılık, özgüllük, pozitif prediktif değer (PPD), negatif prediktif değer (NPD) ve odds ratio (OR) sonuçlarına bakıldığında CA 15-3 için sırasıyla %48, %95, %92, %59 ve +OR 9.6 -OR 0.5; leptin için sırasıyla %52, %75, %72, %55, +OR 2.08 -OR 0.64; IL-6 için %72, %70, %75, %66 2.4-0.5; VEGF için %24, %80, %60, %45, 1.2-0.92; CRP için %68, %30, %55, %43, 0.97-1.06; CK-MB için %8, %70, %25, %38, 026-1.31 değerleri hesaplandı. Sonuç: CA 15-3, IL-6, Leptin, VEGF ve CRP benign-malign over tümörü ayrımında etkin bulundu ancak duyarlılık ve özgüllükleri yeteri kadar kuvvetli olmadığı için rutinde kullanımı kısıtlı olup seçilmiş vakalarda kullanımı uygun olabilir.

🔖

Cite This Article

OĞUZ, H., KURU, O., AKBAYIR, Ö., YASASEVER, V., BERKMAN, S., ŞEN, S. (2022). Adneksiyel kitlelerde malignite prediksiyonunda tümör belirteci olarak serumda crp, vegf, leptin, ck-mb, ca-15-3, ıl-6 bakılması. Journal of the Turkish-German Gynecological Association, Cilt: 12 - Sayı: 4, 214–219. https://ajindex.com/articles/567728

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. American Cancer Society. Cancer facts and figures 2007. Atlanta: American Cancer Society; 2007
  2. Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329: 1550-9
  3. Res LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2004. Bethesda (MD): National Cncer Instıtute; 2007. Based on Novermber 2006 SEER data submission, posted to the SEER web site
  4. Teneriello MG, Park RC. Early detection of ovarian cancer. CA Cancer J Clin 1995; 45: 71-87
  5. Klug TL, Bast RC Jr, Niloff JM, Knapp RC, Zurawski VR Jr. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA-125) associated with human epithelial ovarian carcinomas. Cancer Res 1984; 44: 1048-53
  6. Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998; 16: 1494-7
  7. Schilthuis MS, Aalders JG, Bouma J, Kooi H, Fleuren GJ, Willemse PH, et al. Serum CA-125 levels in epithelial ovarian cancer: relation with findings at second-look operations and their role in the detection of tumour recurrence. Br J Obstet Gynaecol 1987; 94: 202-7
  8. Oei, AL, Massuger LF, Bulten J, et al. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 2006; 94: 814-9
  9. Jacobs U, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004; 3: 355-66
  10. Berek JS, Bark JR RC. The CA 125 tumor associated antigen: a review of the literature. Hum Repr 1989; 4: 1-12
  11. Gadducci A, Ferdeghini M, Prontera C, Moretti L, Mariani G, Bianchi R, et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 1992; 44: 147-54
  12. Gezginç K, Çelik Ç, Bala A, Acar A, Çiçek N, Akyürek C. Comparison of ultrasonography and Ca-125 in differential diagnosis of malign adnexial masses. J Turkish-German Gynecol Assoc 2003; 4: 42-5
  13. Tanrıverdi HA, Sade H, Akbulut V, Barut A, Bayar Ü. Clinical and ultrasonographic evaluation of pelvic masses. J Turkish-German Gynecol Assoc 2007; 8: 67-70
  14. Jacobs IJ, Oram DH, Bast RC Jr. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol 1992; 80: 396-9
  15. Mor G, Visintin I, Lai Y, Zhao H, Schwa